Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 282

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 282
---
 December 2024. In addition, each of the entities agreed to and ultimately purchased 37,500shares of the Company’s Common Stock at a purchase price of $ 1.33per share prior to the effective date of the IPO, resulting in aggregate proceeds of $ 150,000.

Pursuant to the agreements, the counterparties are obligated to perform certain services, as defined, and the Company is recognizing the fair value of the issued restricted shares as compensation expense over the 36-month term, the requisite service period. During the three and nine months ended September 30, 2025 the Company recorded compensation expense of $ 389,707and $ 1,156,410, respectively, related to the agreement, which in general and administrative expenses in the accompanying condensed consolidated statements of operations. There was nosuch expense recorded during the nine months ended September 30, 2024 due to the timing of the execution of the service agreements.

| F-37 |

JUPITER NEUROSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 6 – Stockholders’ Equity, continued

Stock Options

The Company grants stock under the provisions of its 2021 Equity Incentive Plan (“the Plan”).

On January 24, 2024, the Company granted 180,000stock options to a consultant with an exercise price of $ 1.33per share and a grant date fair value of $ 190,560, of which 50% vested immediately with the remaining 50% being vested over a 12 month period.

As discussed in Note 3 – Related Party Transactions - Equity Instruments Exchanged for Accrued Compensation,during the nine months ended September 30, 2024, the Company issued additional options related to accrued compensation.

On June 10, 2025, the Company granted 250,000 stock options to a consultant with an exercise price of $0.97 per share and a grant date fair
value of $191,168, and a 10-year term. The 25% of the stock options vest immediately on the grant date, with the remaining 187,500 options
vesting in equal monthly installments ratably beginning in July 2025 through May 2027.

On July 2, 2025, the Compensation Committee approved the grant of an aggregate of 357,448stock options issued to certain executives. The stock options have an exercise price of $